RJMty19 (CD19-CAR-DNT cells)

Phase 1Biologic

RJMty19 (CD19-CAR-DNT cells) is one of 94 biologic programs targeting Relapsed or Refractory. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Relapsed or RefractoryNot yet recruiting

Systemic Lupus ErythematosusNot yet recruiting

Relapsed or RefractoryPhase 1

Not yet recruiting

Systemic Lupus ErythematosusPhase 1

Not yet recruiting

Competition

Competitive Landscape

134 competitors in Systemic Lupus Erythematosus

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 3

9 2

Medrol

Pfizer

Phase 3

5 3

Rinvoq

AbbVie

Phase 3

3 4

Cytoxan

BBaxter Healthcare Corporation

Phase 3

12 5

Gazyva

Roche

Phase 3

2 6

Sotyktu

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

3 7

Rapamune

PPrism Pharmaceuticals

Phase 3

1 8

Ianalumab

Novartis

Phase 3

3 9

Fludara

Sanofi

Phase 2

6 10

Glucocorticoid

AbbVie

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Not yet recruiting

Relapsed or Refractory

NCT06314828

Q4 2027

Phase 1Not yet recruiting

Systemic Lupus Erythematosus

NCT06340490

Clinical

Trials by Indication[1]

Systemic Lupus Erythematosus1 trial

A Study of RJMty19 in Refractory Systemic Lupus Erythematosus (SLE)

Not yet recruiting·GGuangdong Ruishun Biotech Co., Ltd·Phase 1·NCT06340490·24 enrolled

Relapsed or Refractory1 trial

A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHL

Not yet recruiting·GGuangdong Ruishun Biotech Co., Ltd·Phase 1·NCT06314828·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for RJMty19 (CD19-CAR-DNT cells). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RJMty19 (CD19-CAR-DNT cells) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RJMty19 (CD19-CAR-DNT cells). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Guangdong Ruishun Biotech Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: GGuangdong Ruishun Biotech Co., Ltd

RJMty19 (CD19-CAR-DNT cells)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2027

Trials by Indication[1]

Systemic Lupus Erythematosus1 trial

Relapsed or Refractory1 trial

References

Drug Info

Quick Facts

Related News